Non-Hodgkin’s Lymphoma | Pharmacor | G7 | 2015
Last Updated 2 November 2015
Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year forecast period. This comes despite biosimilar erosion expected for rituximab, the patient share and sales leader in 2014, and generic erosion for bendamustine, the second best-selling agent across the NHL market in 2014. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma – Current Treatment – Current Treatment: Physician Insights – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes…
Report
Non-Hodgkin’s Lymphoma – Current Treatment – Treatment Sequencing – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Hodgkin’s Lymphoma – Geographic Focus: China – China In-Depth – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…
